A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
Phase 2 Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer
About This Trial
- This study is testing whether a structured exercise program can help manage early-stage prostate cancer compared to standard care.
- It is designed for adult men who are monitoring their cancer through active surveillance rather than getting immediate treatment, and who do not currently get much regular physical activity.
- Before taking part, you will wear an activity tracker for a week and undergo basic health and heart checks to make sure it is safe for you to exercise.
- You may not be eligible if you have received cancer treatments in recent years or are currently taking part in another weight loss program.
More Information
- To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.
Who Can Enroll
- Age Range: 18 years and older
- Gender: Male
- Who This Trial is For: This study is testing whether a structured exercise program can help manage early-stage prostate cancer compared to standard care.
Study Details
- Start Date: February 10, 2023
- Lead Sponsor: City of Hope Medical Center
Full Eligibility Criteria
Inclusion Criteria
- Age ≥ 18
- Men with histologically confirmed localized prostate cancer undergoing active surveillance.
- Inactive, defined as not meeting the national exercise guidelines for cancer patients (<150 minutes/week of moderate or vigorous exercise)43 as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry (general physical activity screening assessment via smart watch).
- Screening clearance by an MSK Exercise Physiologist (i.e., review of ECG)
- BMI <40 kg/m^2
- Cleared for exercise participation as per pre-screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+) (Appendix B)
Exclusion Criteria
- Enrollment in any other program that may alter the impact of exercise on tumor outcomes (e.g., weight loss program)
- Any neoadjuvant anticancer treatment of any kind for prostate cancer in the last 5 years
- Any history of systemic anticancer therapy in the last 15 years
- Distant metastatic malignancy of any kind
- Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
Treatments
- Behavioral: Exercise Therapy